FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
ETHZilla Corporation Common Stock Stock AnalysisComprehensive stock analysis for ETHZilla Corporation Common Stock (ATNF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisATNF
ATNF
ETHZilla Corporation Common Stock
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ATNF
Home🔹Stocks🔹ETHZilla Corporation Common Stock

ETHZilla Corporation Common Stock

ATNF•NASDAQ

ETHZilla Corporation Common Stock

ATNF•NASDAQ
Market cap
$1.08B
Sentiment

Your view on ATNF

Mkt Cap
$1.08B
Sentiment
Your view
ATNF
ETHZilla Corporation Common Stock
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
ATNF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About ETHZilla Corporation Common Stock

Industry
Biotechnology
Sector
Healthcare
CEO
Lloyd Blair Jordan
Headquarters
US
Industry
Biotechnology
Sector
Healthcare
CEO
Lloyd Blair Jordan
Headquarters
US
Description

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News